US$28m is what management estimated to be spent, mostly on manufacturing and operating (US$16.7m) which if you recall previous annoucnements is probably due to the two new distribution centres being built and the move from one shift to three shifts on their Aspiral production line in China.
US$22m is the estimated inflow from customer receipts, which suggests a US$6m net outflow in Q4.
FLC completed a cap raise which will bring in around US$25m.
In terms of the timing of when the US$20m in revenue is recognised... that is purely accounting and has nothing to do with cash flow. So I am not sure what you are suggesting here.. are you confusing two different concepts here? Either way the cash disbursements are coming in FY20, probably Q1 2020... which should be a pretty impressive quarter for cash flow.
And for what its worth, I think the revenue should be recognised in Q1 2020. Accounting standards are conservative, they will make you recognise expenses post balance sheet, but unlikely to fast track revenue recognition.
US$28m is what management estimated to be spent, mostly on...
Add to My Watchlist
What is My Watchlist?
